Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $72.79 USD
Change Today 0.00 / 0.00%
Volume 0.0
CHGCY On Other Exchanges
As of 8:10 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by CHUGAI PHARMACEUTIC-UNSP ADR (CHGCY) in the last 6 months

Announced 04/3/15
Chugai Pharmaceutical Co. Ltd., Manufacturing and Marketing Approval Right of Two Antithyroid Drugs

ASKA Pharmaceutical Co.Ltd. (TSE:4514) signed a contract to acquire manufacturing and marketing approval right of two antithyroid drugs from Chugai Pharmaceutical Co. Ltd. (TSE:4519) on April 3, 2015. The transaction is expected to close on October 1, 2015.

CHGCY's price was unchanged after the transaction was announced on 04/3/15.
Investor / Buyer
ASKA Pharmaceutical Co.Ltd.
Creditor / Lender
Chugai Pharmaceutical Co. Ltd.
Announced 02/28/15
1.42B for iPS PORTAL,Inc.
Private Placement

iPS Portal, Inc. announced the signing of a share subscription agreement for the issue of A class preferred shares for gross proceeds of ¥1.42 billion in the end of February 2015. The transaction included participation from 13 investors, Shimadzu Corporation, Eisai Co., Ltd., Ajinomoto Co., Inc., Sysmex Corporation, Shin Nippon Biomedical Laboratories, Ltd., SCREEN Holdings Co., Ltd., Toho Holdings Co., Ltd., Chugai Pharmaceutical Co., Ltd., Horiba, Ltd., Daiichi Jitsugyo ...
Read More

CHGCY's price was unchanged after the transaction was announced on 02/28/15.
Investor / Buyer
Ajinomoto Co., Inc.
Chugai Pharmaceutical Co. Ltd.
Daiichi Jitsugyo Co. Ltd.
Daiwa Capital Holdings Co., Ltd.
Eisai Co., Ltd.
SCREEN Holdings Co., Ltd.
Shimadzu Corporation
Shin Nippon Biomedical Laboratories, Ltd.
SMBC Venture Capital Co., Ltd.
Sumitomo Mitsui Banking Corp., Investment Arm
Sysmex Corp.
Toho Holdings Co., Ltd.
Announced 02/24/15
500.00M for NanoCarrier Co., Ltd.
Private Placement

NanoCarrier Co., Ltd. (TSE:4571) announced a private placement of 389,400 shares at ¥1,284 per share with new investor, Chugai Pharmaceutical Co. Ltd. for gross proceeds of ¥499,989,600 on February 24, 2015. The investor will acquire 0.96% stake of the company through this transaction. The net proceeds from the transaction will be ¥494,989,600, after deducting estimated amount of issuance fees of ¥5,000,000, which includes registration fees and license taxes ¥ 2,500,000 ...
Read More

CHGCY's price was unchanged after the transaction was announced on 02/24/15.
Investor / Buyer
Chugai Pharmaceutical Co. Ltd.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CHGCY:US $72.79 USD 0.00

CHGCY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $70.01 USD -0.15
Eli Lilly & Co $84.51 USD -0.03
Hospira Inc $89.45 USD +0.05
Merck KGaA €92.61 EUR -0.64
Teva Pharmaceutical Industries Ltd $69.02 USD -0.05
View Industry Companies

Industry Analysis


Industry Average

Valuation CHGCY Industry Range
Price/Earnings 46.6x
Price/Sales 5.1x
Price/Book 4.0x
Price/Cash Flow 47.8x
TEV/Sales 4.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHUGAI PHARMACEUTIC-UNSP ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at